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ABSTRACT  
 
Genome-wide association studies (GWASs) have shown that common genetic variation 
contributes to the heritable risk of childhood acute lymphoblastic leukemia (ALL). To identify 
new susceptibility loci for the largest subtype of ALL, B-cell precursor ALL (BCP-ALL), we 
conducted a meta-analysis of two GWAS with imputation using 1000 Genomes and UK10K 
Project data as reference (totaling 1,658 cases and 7,224 controls). After genotyping an 
additional 2,525 cases and 3,575 controls we identify new susceptibility loci for BCP-ALL 
mapping to 10q26.13 (rs35837782, LHPP, P = 1.38x10-11) and 12q23.1 (rs4762284, ELK3, P = 
8.41×10-9). We also provide confirmatory evidence for the existence of independent risk loci at 
9p21.3, but show that the association marked by rs77728904 can be accounted for by linkage 
disequilibrium with the rare high-impact CDKN2A p.Ala148Thr variant rs3731249. Our data 
provide further insights into genetic susceptibility to ALL and its biology.  
 
Key words: 10q26.13, 12q23.1, risk, B-cell, acute lymphoblastic leukemia  
 
Running title: 10q26.13, 12q23.1 variants influence childhood ALL risk  
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INTRODUCTION 
 
Acute lymphoblastic leukemia (ALL) is the major pediatric cancer in western countries, with B-cell 
precursor (BCP) ALL accounting for approximately 80% of ALL cases1. Despite this, the etiology of 
ALL is poorly understood and although there is indirect evidence for an infective origin, no specific 
environmental risk factor has been identified2, 3. Evidence for inherited predisposition to ALL is 
provided by the increased risk shown in siblings of cases independent of the concordance in 
monozygotic twins, which has an in utero etiology4. Support for polygenic susceptibility to ALL has 
come from genome-wide association studies (GWAS)5-9. While these studies have so far identified 
single-nucleotide polymorphisms (SNPs) at seven loci influencing BCP-ALL at 7p12.2 (IKZF1), 
9p21.3 (CDKN2A, two risk loci), 10p12.2 (near PIP4K2A), 10p14 (GATA3), 10q21.2  (near ARID5B) 
and 14q11.2 (near CEBPE), statistical modelling using Genome-Wide Complex Trait Analysis 
predicts that additional risk loci conferring modest effects should be identifiable by further 
GWAS10.  
 
Recovery of untyped genotypes through imputation provides a mechanism of exploiting GWAS 
datasets to identify new risk alleles11. Additionally it enables fine mapping and refinement of 
association signals, for example, in identification of the CDKN2A p.Ala148Thr variant rs3731249 
(hg19 chr9:g.21970916 G>A) as contributing to the 9p21.3 association signal8. Recently, the use of 
the 1000 Genomes Project and the UK10K projects as a combined reference panel has been shown 
to improve imputation accuracy compared with using the 1000 Genomes Project data alone12, 13. 
 
Here we report imputation using the 1000 Genomes and the UK10K Project data as reference and 
meta-analysis of two GWAS to identify new susceptibility alleles for BCP-ALL. After replication 
genotyping in three additional case-control series we have identified new risk loci for BCP-ALL at 
10q26.13 and 12q23.1. Our findings provide further insights into the genetic and biological basis of 
this hematological malignancy. 
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METHODS 
 
Ethics 
Collection of samples and clinico-pathological information from subjects was undertaken with 
informed consent in accordance with the Declaration of Helsinki and ethical board approval. 
Ethical committee approval was obtained for Medical Research Council UKALL97/99 trial by 
individual UK treatment centers and approval for UKALL2003 was obtained from the Scottish 
Multi-Centre Research Ethics Committee (REC:02/10/052)14, 15. Additional ethical approval was 
obtained under the auspices of the Childhood Leukaemia Cell Bank, the United Kingdom Childhood 
Cancer Study and University of Heidelberg. 
 
GWAS data 
The United Kingdom (UK)-GWAS and German-GWAS data sets have been previously reported6, 7. 
Briefly, the UK-GWAS was based on constitutional DNA (i.e. remission samples) of 459 white BCP-
ALL cases from the United Kingdom Childhood Cancer Study (UKCCS; http://www.ukccs.org/; 258 
male; mean age at diagnosis 5.3 years); 342 cases from the UK Medical Research Council (MRC) 
ALL 97/99 (1997-2002) trial (190 male; mean age of diagnosis 5.7 years) and 23 cases from 
Northern Institute for Cancer Research (16 male). Genotyping was performed using Illumina 
Human 317K arrays (Illumina, San Diego; Available at: http://www.illumina.com). For controls we 
used publicly accessible data generated by the Wellcome Trust Case Control Consortium 2 
(http://www.wtccc.org.uk/) from 2,699 individuals in the 1958 British Birth Cohort (Hap1.2M-Duo 
Custom array data) and 2,501 individuals from the UK Blood Service. The German GWAS was 
comprised of 1,155 cases (620 male; mean age at diagnosis 6.0 years) ascertained through the 
Berlin-Frankfurt-Münster (BFM) trials (1993-2004) genotyped using Illumina Human OmniExpress-
12v1.0 arrays. For controls we used genotype data from 2,132 healthy individuals from the Heinz 
Nixdorf Recall (HNR) study; consisting of 704 individuals genotyped using Illumina-HumanOmni1-
Quad_v1 and 1,428 individuals genotyped on Illumina-HumanOmniExpress-12v1.0 platform. In 
total we obtained 1,658 BCP ALL cases and 7224 matched controls from the two GWAS series 
combined. 
 
Quality control of GWAS samples  
The quality control steps of UK and GERMAN GWAS study samples have been have been described 
in previous studies6, 7. After quality control steps  we obtained 824 cases and 5,200 controls for the 
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UKGWAS data set and 834 cases and 2,024 controls from the German data sets that were then 
used for further genotyping and imputation analysis.  
 
Replication series and genotyping 
The UK replication series comprised 1,150 patients (504 male; mean age at diagnosis 6.2 years) 
ascertained through the UK ALL-2003 (2003-2011) and ALL-97/99 trials14, 15. Immunophenotyping 
of diagnostic samples was undertaken using standard methods. The 2,100 controls (702 male) 
were ethnically-matched healthy individuals with no personal history of cancer recruited to the 
National Study of Colorectal Cancer Genetics (NSCCG)16 and the Genetic Lung Cancer 
Predisposition Study (GELCAPS)17. Genotyping of cases and controls was performed using 
competitive allele-specific polymerase chain reaction KASPAR chemistry (LCG Biosciences Ltd., 
Hertfordshire, UK). The German replication series consisted of 1,501 patients ascertained (794 
males; mean age at diagnosis, 6.2 years ascertained through the BFM trials (1993-2004)18. The 
controls comprised 1,516 individuals (762 males; mean age, 58.2 years) ethnically-matched 
healthy individuals of German origin recruited at the Institute of Transfusion Medicine in 
Manheim, Germany, 2004. Samples having SNP call rates of <90% were excluded from the 
analysis. To ensure quality of genotyping in all assays, at least 2 negative controls and 1% to 2% 
duplicates (concordance >99.9%) were genotyped. All primers and probes used are detailed in 
Table S8. Combing both replication series we had access to 2,651 B-cell ALL cases and 3,616 
matched controls for the current study. 
 
Sanger sequencing 
To confirm the fidelity of imputation a random subset of samples were sequenced using BigDye® 
Terminator v3.1 Cycle Sequencing Kit (Life Technologies) in conjunction with ABI 3700xl semi-
automated sequencers (Applied Biosystems). Primer sequences are detailed in Table S10.  
 
Statistical and bioinformatics 
Main data analysis were undertaken using R version 2.15.2 (R Core Team, 2013; http://www.R-
project.org/), PLINK v1.919 and SNPTEST v2.4.1 software20. The two GWAS data sets were imputed 
for over 10 million variants using IMPUTE2 v2.3.0 software 21, 22 and data from the 1000 Genomes 
Project (Phase 1 integrated variant set, v3.20101123, http://www.1000genomes.org, 9 December 
2013) and UK10K (ALSPAC, EGAS00001000090 / EGAD00001000195, and TwinsUK, 
EGAS00001000108 / EGAD00001000194, studies only; http://www.uk10k.org/) as reference. Data 
©    2016 Macmillan Publishers Limited. All rights reserved.
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sets were first phased using SHAPEIT v2.12 prior to imputation to accurately estimate 
haplotypes23. The adequacy of case-control matching and possibility of differential genotyping 
between cases and controls was evaluated using quantile-quantile plots of test statistics to 
compute λ100. Test of association between imputed SNPs and childhood ALL was performed using 
a missing data likelihood score test under a frequentist additive model in software SNPTEST. 
Eigenvectors for the German data set were inferred using smartpca component within EIGENSOFT 
v2.424, 25 and Eigenstrat adjustment was carried out by including the first 2 eigenvectors as 
covariates in SNPTEST during association analysis. Post imputation and SNPTEST, only markers 
with info scores >0.4, imputed call rates/SNP >0.9, MAFs >0.005 and a posterior imputation quality 
threshold of 0.5 or higher were included in further analysis. SNPs that deviated from Hardy 
Weinberg equilibrium (HWE) at P-values <10-5 were also excluded from further analysis. Meta-
analysis of post QC GWAS datasets was conducted in META 1.3.120, 21, 26, under a fixed-effects 
model using the inverse variance approach. We calculated Cochran's Q statistic to test for 
heterogeneity and the I2 statistic to quantify the proportion of the total variation attributable to 
heterogeneity27. The presence of secondary association signals due to allelic heterogeneity in risk 
loci were carried out using a conditional analysis in SNPTEST by adjusting for the sentinel SNP 
using the ‘–condition-on’ option. Logistic regression association analysis and meta-analysis of the 
replication data sets under fixed-effects were carried out using STATA v.10 software (Stata 
Corporation, College Station, TX, USA). 
 
Linkage disequilibrium (LD) metrics were calculated using vcftools v0.1.12b26 
(http://vcftools.sourceforge.net) using UK10K data. HapMap recombination rate (cM/Mb) were 
defined by Oxford recombination hotspots28, 29. 
 
Chromatin state dynamics 
To explore the epigenetic profile of association signals, we used 15-state chromatin segmentation 
data learned by computationally integrating chIP-seq data for GM12878 lymphoblastoid cells 
inferred from ENCODE Histone Modification data (H4K20me1, H3K9ac, H3K4me3, H3K4me2, 
H3K4me1, H3K36me3, H3K27me3, H3K27ac, and CTCF) and binarized using a multivariate Hidden 
Markov Model (http://genome.ucsc.edu/ENCODE/)30. Risk SNPs and their proxies (i.e., r2 > 0.8 in 
the 1000 Genomes EUR reference panel) were annotated for putative functional effect using 
HaploReg v331 and RegulomeDB32 and SeattleSeq33 Annotation. These servers make use of data 
from ENCODE30, genomic evolutionary rate profiling (GERP)34 conservation metrics, combined 
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annotation dependent depletion (CADD) scores35 and PolyPhen scores36. Similarly we searched for 
overlap with “super-enhancer” regions as defined by Hnisz et al, 37 restricting analysis to GM12878 
cells.  
 
Expression quantitative trait locus analysis 
Expression quantitative trait locus (eQTL) analysis was performed for all genes in 1Mb regions 
spanning rs4762284 and rs35837782 by querying mRNA expression data from MuTHER38 and 
Blood eQTL browser39. 
 
Chromosome karyotyping and 9p21.3 deletion status 
Conventional cytogenetic studies on diagnostic ALL tumor cells were conducted using standard 
karyotyping methodologies, and standard criteria for the definition of a clone were applied. 
Genomic copy number at 9p21.3 was assayed using FISH and MLPA as previously described40, 41 
 
Relationship between SNP genotype and survivorship 
To investigate if genotype is associated with clinical phenotype or outcome, we analysed data on 
patients recruited to AIEOP-BFM 200018. Briefly, patients received standard chemotherapy (i.e., 
prednisone, vincristine, daunorubicin, l-asparaginase, cyclophosphamide, ifosfamide, cytarabine, 
6-mercaptopurine, 6-thioguanine, and methotrexate) with a subset of high-risk patients treated 
with cranial irradiation and/or stem cell transplantation. Event-free survival (EFS) was defined as 
the time from diagnosis to the date of last follow-up in complete remission or to the first event. 
Events were resistance to therapy (nonresponse), relapse, secondary neoplasm, or death from any 
cause. Failure to achieve remission due to early death or nonresponse was considered as an event 
at time zero and patients lost to follow-up were censored at the time of their withdrawal. Patients 
were stratified into 3 categories: standard, intermediate, and high risk. Although minimal residual 
disease (MRD) analysis was the main stratification criterion, high risk was also defined by 
prednisone poor-response or ≥5% leukemic blasts in bone marrow on day 33, or t (9;22)/t(4;11) 
positivity or their molecular equivalents (BCR-ABL/MLL-AF4-fusion) independent of MRD status. 
Standard patients were MRD-negative on treatment day 33 (TP1) and 78 (TP2) and had no high-
risk criteria. High-risk patients were defined as having residual disease (≥10−3 cells) at TP2. 
Intermediate patients had positive-MRD detection at either TP1 or TP2, but had a cell count of 
<10-3 at TP2. The Kaplan–Meier method was used to estimate survival rates, differences were 
compared with the two-sided log-rank test42, 43. Cumulative incidence functions for competing 
©    2016 Macmillan Publishers Limited. All rights reserved.
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events were constructed by the method of Kalbfleisch and Prentice and were compared employing 
the Gray's test44, 45. Computations were performed using SASv9.1 (SAS, Cary, NC, USA). 
 
Heritability analysis 
We used Genome-wide Complex Trait Analysis (GCTA) to estimate the polygenic variance (i.e. 
heritability) ascribable to all GWAS SNPs 46. SNPs were excluded based on minor allele frequency 
(<0.01), missing genotype rate (0.05) and deviation from HWE (P<0.05).  Individuals were excluded 
for exhibiting an excess of missing genotype (>0.02) and where two individuals were closely 
related (genetic relatedness score > 0.05). A genetic relationship matrix (GRM) of pairs of samples 
was used as input for the restricted maximum likelihood analysis to estimate the heritability 
explained by the selected set of SNPs. Regions of  high LD in the genome were excluded from the 
analysis. Imposing a prevalence of 0.00052 for childhood ALL we estimated the heritability 
explained by risk SNPs identified by GWAS as located within autosomal regions associated with 
ALL. For each risk SNP the heritability was estimated for all chromosomes simultaneously using the 
risk SNP genotype as a covariate. In chromosomes bearing multiple independent risk loci, all the 
risk SNPs in that chromosome were used as covariates to get the combined contribution of risk 
SNPs towards heritability. The heritability associated with the risk SNPs was taken to be the 
difference between the heritability of the chromosome on which it is found as calculated with and 
without covariate adjustment for the SNP.  
 
Calculation of polygenic risk scores 
In addition to the two new risk loci described here seven previously reported risk loci were 
included in the calculation of the Polygenic Risk Scores (PRS) for childhood ALL (rs10828317, 
10p12.2; rs3824662, 10p14; rs7089424, 10q21.2; rs2239633, 14q11.2; rs4132601, 7p12.2; 
rs3731249, 9p21.3; rs3731217, 9p21.3; rs35837782, 10q26.13; rs4762284, 12q23.1). The eight 
variants are thought to act independently as previous studies have shown no interaction between 
risk loci5-7. PRS were constructed using methods established by Pharoah et al, based on log-normal 
distribution LN(μ,σ2) of  mean μ, and variance σ2 (i.e. relative risk is normally distributed on a 
logarithmic scale)47. Standardized incidence ratios for familial risk in singleton siblings and twins 
for childhood ALL were assumed to be 3.24. Familial risk was calculated by dividing polygenic 
variation over the square root of familial risk. 
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RESULTS 
 
Association analysis 
 
To identify new susceptibility loci for BCP-ALL we conducted a pooled meta-analysis of two GWAS 
in populations of European ancestry, the UK-GWAS and the German-GWAS (see Methods). After 
filtering, the studies provided genotype data on 1,658 cases and 7,224 controls. To achieve 
consistent and dense genome-wide coverage, we imputed unobserved genotypes at >10 million 
SNPs using a combined reference panel comprising 1,092 individuals from the 1000 Genomes 
Project and 3,781 individuals from the UK10K project. Quantile-quantile plots of SNPs (minor allele 
frequency (MAF) >0.5%) post-imputation did not show evidence of substantive over-dispersion 
introduced by imputation (genomic inflation λ100 for UK and German GWAS was 1.016 and 1.009 
respectively; Figure S1). 
 
Pooling data from both GWAS we derived joint odds ratios (ORs) and 95% confidence intervals 
(CIs) under a fixed-effects model for each SNP with MAF >0.5% and associated per allele P values. 
From this analysis we identified the top ranked SNPs in 20 distinct regions and not previously 
implicated in the risk of developing BCP-ALL (Table S1). After confirming the fidelity of imputation 
by Sanger sequencing (Table S2) we successfully designed and optimized allele-specific PCR 
(KASPAR) assays for 14 SNPs.  We sought validation of associations by genotyping additional UK 
and German case-control series totaling 2,525 cases and 3,575 controls (Table S3). 
 
In the combined analysis of data from these replication series, rs35837782 (10q26.13, hg19 
chr10:g.126293309) and rs4762284 (12q23.1, hg19 chr12:g.96612762) showed significant support 
for an association with BCP-ALL, with P-values and ORs of 3.66 x 10-6, 1.20 and 3.88x10-4 , 1.16 
respectively (Table 1; Table S4; Figure S3). In a meta-analysis of the discovery GWAS and 
replication series, these associations attained genome-wide significance (rs35837782, P = 1.38 × 
10-11) and (rs4762284, P = 8.41 × 10-9) (Table 1; Table S4; Figure S3).  
 
Conditional association analyses 
To explore the possibility of multiple risk loci at 10q26.13 and 12q23.1 and previously identified 
GWAS risk loci we performed conditional analyses. At 10q26.13 and 12q23.1 we found no 
©    2016 Macmillan Publishers Limited. All rights reserved.
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evidence for signals independent of SNPs rs35837782 and rs4762284. Similarly at 7p12.2, 10p12.2, 
10p14, 10q21.2 and 14q11.2 we found no support for the existence of multiple risk loci.  
 
We and others have recently sought to decipher the GWAS signal at the 9p21.3 locus8, 48-50. Our 
conditional analysis supports the assertion of an additional locus in this region, independent of the 
original GWAS SNP rs3731217, which is best captured by the rare coding SNP rs3731249 
(MAF=0.03 in CEU, r2=0.005, D’=1.00 with rs3731217; Table S5). rs3731249, encoding CDKN2A 
p.Ala148Thr, has been shown to reduce tumor suppressor function of p16INK4A, increase 
susceptibility to leukemic transformation of hematopoietic progenitor cells and to be 
preferentially retained in ALL cells49. The more common variant rs662463 correlated with 
rs77728904 has concurrently been suggested as a plausible causative variant underlying this new 
association signal48 (MAF=0.07, r2=0.16, D’=1.00 with rs3731249). Despite some evidence that 
rs77728904 variant is a cis-eQTL for CDKN2B48, this association signal is entirely captured by 
rs3731249 (P-values before and after conditioning: 6.26 x 10-7and 0.10 respectively; Table S5). 
Here our analysis has been constrained to the identification of variants which can be imputed with 
high fidelity, hence it does not exclude the possibility of rarer variants with higher impact, 
especially indels potentially impacting on ALL risk. This exemplifies the difficultly in elucidating the 
genetic basis of such functionally rich genomic regions. Once correcting for these two signals, no 
additional statistically significant association was detected in this region. 
 
Relationship between the new ALL risk SNPs and tumor profile 
Given the biological heterogeneity of BCP-All, we analyzed the association between rs35837782 
and rs4762284 genotypes and the major subtypes of BCP-ALL, hyperdiploidy (i.e. >50 
chromosomes), ETV6-RUNX1 and others (Table S4; Figure S3). Analysis of these data provided no 
consistent evidence that the risk of rs35837782 and rs4762284 was confined to hyperdiploid, 
ETV6-RUNX1 or non-hyperdiploid/non-ETV6-RUNX1 subtypes of B-ALL. Similarly, we found no 
evidence for a relationship between rs35837782 and rs4762284 genotypes and other 
chromosomally defined forms of BCP-ALL defined by t(9;22)(q34;q11), t(1;19)(q23;p13), and 
t(4;11)(q21;q23) karyotype or CDKN2A deletion status after adjustment for multiple testing (Table 
S6). Finally, we found no evidence that rs35837782 and rs4762284 genotype was associated with 
age at diagnosis or sex or influenced patient outcome as defined by event-free survival by 
analyzing data on 810 patients from the AIEOP-BFM 2002 trial (Figure S4, Table S7, and Table S8).   
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Impact on the heritable risk  
By fitting all SNPs from GWAS simultaneously, the estimated heritability of ALL attributable to all 
common variation is 12.1% (± 3.8%). This estimate represents the additive variance and therefore, 
does not include the potential impact of gene-gene interactions or dominance effects or gene-
environment interactions impacting on ALL risk. Moreover, given the evidence, albeit indirect, of a 
role for infectious exposure in relation to ALL risk, it is possible that substantive gene-environment 
effects operate. While the currently identified risk SNPs (newly discovered and previously 
identified) only account for 19% of the additive heritable risk the OR effect sizes of the ALL risk 
SNPs are among the highest reported in GWAS of any cancer type and in combination they impact 
significantly on disease risk with those in the top 1% of genetic risk having a 6.2-fold relative of ALL 
(Figure S5).  The power of our GWAS to identify common alleles conferring relative risks of 1.5 or 
greater (such as the 7p12.2 variant) is high (~80%). Hence, there are unlikely to be many additional 
SNPs with similar effects for alleles with frequencies greater than 0.3 in populations of European 
ancestry. In contrast, our analysis had limited power to detect alleles with smaller effects and/or 
MAF<0.1. 
 
Biological inference 
 
At 10q26.13, rs35837782 localizes to intron 6 on the gene encoding phospholysine 
phosphohistidine inorganic pyrophosphate phosphatase (LHPP; Fig. 1) with genes FAM53B and 
METTL10 mapping nearby. The SNP rs4762284 at 12q23.1 maps to intron 1 of the gene encoding 
the ETS-domain protein (ELK3) , with nearby genes including CDK17 (Fig.1). 
 
To explore the epigenetic profile of association signals at each of the two new risk loci we used 
HaploReg and RegulomeDB to examine  whether the sentinel SNPs and those in high LD (i.e., r2 > 
0.8 in the 1000 Genomes EUR reference panel) annotate putative transcription factor binding or 
enhancer elements (Table S9). The SNP rs4762284 resides within a region of open chromatin, 
common across multiple cell lines, consistent with a regulatory element such as an enhancer or a 
promoter. To gain further insight into the functional basis of rs35837782 and rs4762284 
associations we examined for an association between SNP genotype and expression of genes 
mapping within 1Mb of sentinel SNPs. We made use of publicly available expression data on blood 
cells, lymphoblastoid cell lines from HapMap3, Geneva, and the Multiple Tissue Human Expression 
©    2016 Macmillan Publishers Limited. All rights reserved.
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Resource pilot data. In blood rs4762284 genotype was associated with ELK3 expression at P = 6.85 
x 10-4) with the risk allele correlated with reduced expression (Table S10)39.  
 
DISCUSSION 
 
In this analysis of BCP-ALL, we have identified common variants at 10q26.13 and 12q23.1. It has 
recently been proposed that many GWAS signals are a consequence of ‘synthetic associations’, 
resulting from the combined effect of one or more rare causal variants rather than simply LD with 
a common risk variant51, 52.  Support for such a model in ALL is provided by the rare high-impact 
variant rs3731249 in CDKN2A8 which is in LD with rs77728904. Since imputation using UK10K as 
reference can accurately recover genotypes for variants with MAFs of 0.5%12 the possibility that 
either 10q26.13 or 12q23.1 associations have a similar genetic basis is highly unlikely.  
 
Given the existence of immuno-genetic subtypes of BCP-ALL,  it is perhaps not surprising there is 
variability in the genetic effects on ALL risk by subtype, with 10q21.2 variants influencing 
hyperdiploid ALL and 10p14 variants influencing non-hyperdiploid/non-ETV6-RUNX1  disease6, 7. In 
contrast to the 7p12.2 and 10p12.2 risk variants6, 7 the 10q26.13 and 12q23.1 loci have generic 
effects on the development of ALL.  
 
Because rs35837782 and rs4762284 localize to LHPP and ELK3, respectively, it is plausible that the 
functional basis of these associations are mediated through these genes. ELK3, an ETS-domain 
transcription factor is an attractive candidate for defining ALL susceptibility a priori since it plays a 
role in both B-cell development and IgH gene regulation53. ELK3, which is a member of ETS family 
of transcription factors, interacting with TCF3 transcription factor 3 (E2A immunoglobulin 
enhancer-binding factors E12/E47)  which is involved in several ALL specific gene fusions including 
TCF3-PBX1/t(1;19)(q23;p13) and TCF3-HLF/t(17;19)(q23;p13) ALL54. ELK3 is highly expressed 
primarily at the early stages of B-lymphocyte development with expression declining drastically 
upon B-cell maturation, correlating with the activity of the enhancer of the immunoglobulin heavy 
chain53. Hence genetically determined reduced expression is compatible with B-cell developmental 
arrest, a hallmark of ALL.  In contrast to ELK3 evidence for a role for LHPP, which encodes a 
diphosphatase, in B-cell development or B-cell malignancy is yet to be established55. While the 
identified risk SNPs map within regions of active chromatin within B-cells and thus have a role in 
©    2016 Macmillan Publishers Limited. All rights reserved.
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the B-cell cis-regulatory network a priori, additional laboratory follow-up is required to decipher 
their functional basis.  
 
In summary, our findings represent a further important step in defining the contribution of 
inherited genetic variants to the risk of developing ALL. Our current and previous findings are 
notable because we have defined associations of several regions with susceptibility to ALL, and 
these regions harbor plausible candidate genes for further investigation. Moreover they 
emphasize the role of genetically determined expression of B-cell developmental genes being key 
players in ALL. Given that there remains significant missing heritability for ALL, future GWAS-based 
studies in concert with functional analyses are likely to lead to further insights into ALL biology. 
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FIGURE LEGEND 213 
 214 
Figure 1:  Regional plots of association results and recombination rates for the newly identified 215 
risk loci for BCP-ALL (a-b). Results for 10q26.13 (rs35837782, a) and 12q23.1 (rs4762284, b). Plots 216 
(using visPig) show association results of both genotyped (triangles) and imputed (circles) SNPs in 217 
the GWAS samples and recombination rates. −log10 P values (y axes) of the SNPs are shown 218 
according to their chromosomal positions (x axes). The sentinel SNP in each combined analysis is 219 
shown as a large circle or triangle and is labelled by its rsID. The color intensity of each symbol 220 
reflects the extent of LD with the top genotyped SNP, white (r2 = 0) through to dark red (r2 = 1.0). 221 
Genetic recombination rates, estimated using UK10K Genomes Project samples, are shown with a 222 
light blue line. Physical positions are based on NCBI build 37 of the human genome. Also shown 223 
are the relative positions of genes and transcripts mapping to the region of association. Genes 224 
have been redrawn to show their relative positions; therefore, maps are not to physical scale. The 225 
lower panel is the chromatin-state segmentation track (ChromHMM) for lymphoblastoid cells 226 
using data from the HapMap ENCODE Project. 227 
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Case genotypes  Control genotypes      
rs35837782 (10q26.13, LHPP) RAF AA AG GG RAF AA AG GG ORa 95% CIb P-value 
UK GWAS 0.67 93 358 373 0.62 745 2,510 1,945 1.27 (1.14-1.41) 2.04X10-5 
German GWAS 0.67 93 365 376 0.63 268 952 804 1.19 (1.05-1.36) 0.0072 
Meta        1.24 (1.14-1.34) 6.04 X 10-7 
UK replication 1 0.67 73 211 251 0.62 150 475 405 1.19 (1.03-1.39) 0.022 
UK replication 2 0.67 56 265 253 0.61 167 497 391 1.33 (1.14-1.55) 0.0002 
German replication 0.65 184 607 621 0.63 204 701 574 1.13 (1.02-1.26) 0.0203 
Meta        1.20 (1.11-1.29) 3.66 X 10-6 
Combined meta                 1.21 (1.15-1.28) 1.38X10-11 
           (Phet= 0.48, I
2= 0%) 
rs4762284 (12q23.1,ELK3) RAF AA AT TT RAF AA AT TT ORa 95% CIb P-value 
UK GWAS 0.33 373 358 94 0.30 2,578 2,160 462 1.18 (1.05-1.32) 0.0046 
German GWAS 0.33 372 366 95 0.28 1,072 773 179 1.30 (1.14-1.49) 1.01X10-4 
Meta        1.23 (1.13-1.34) 2.87X10-6 
UK replication 1 0.31 258 227 52 0.30 497 408 98 1.03 (0.88-1.21) 0.6870 
UK replication 2 0.34 232 287 52 0.29 534 434 85 1.30 (1.11-1.53) 0.0008 
German replication 0.31 650 625 124 0.28 746 619 109 1.15 (1.02-1.29) 0.0178 
Meta        1.16 (1.07-1.25) 3.85X10-4 
Combined meta                 1.19 (1.12-1.26) 8.41X10-9 
           (Phet= 0.17, I
2= 38%) 
 
Table 1.  Risk to childhood acute lymphoblastic leukemia at loci 10q26.13 and 12q23.1.RAF: Risk Allele Frequency for rs35837782 is G and risk allele for 
rs4762284 is T, a. OR: Odds Ratio, b. CI: Confidence Interval.  
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